Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Atezolizumab and Tiragolumab in Cisplatin-Ineligible High-Risk Urothelial Carcinoma
NCT05394337Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2023
- Primary completion
- Dec 2028
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of tiragolumab in urothelial carcinoma (UC), sponsored by University of Texas MD Anderson Cancer Center. Started Feb 2023; status: active, not recruiting.
02
Drugs
tiragolumab
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT05394337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05394337.